Safety and efficacy of denosumab in giant-cell tumour of bone

The Lancet Oncology

Volumn 11, Issue 6, 2010, Pages 513-514

  Kyrgidis, Athanassios ^a   Toulis, Konstantinos ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b 424 General Army Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB;

BONE METASTASIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DENTAL CARE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; LETTER; MEDICAL DECISION MAKING; ORTHOPEDIC SURGERY; OSTEOCLASTOMA; PATIENT MONITORING; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; GIANT CELL TUMOR OF BONE; HUMANS; JAW DISEASES; OSTEONECROSIS; RANK LIGAND;

EID: 77953527103     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70059-0     Document Type: Letter

References (9)

1. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
2. Balke M, Hardes J Denosumab: a breakthrough in treatment of giant-cell tumour of bone?. Lancet Oncol 2010, 11:218-219.
3. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 2009, 7:12.
4. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl 2009, 7:2-3.
5. Kyrgidis A, Toulis KA Denosumab-related osteonecrosis of the jaws. Osteoporos Int 2010, published online March 20. 10.1007/s00198-010-1177-6.
6. Kyrgidis A, Triaridis S, Vahtsevanos K, Antoniades K Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Exp Rev Anticancer Ther 2009, 9:1125-1134.
7. Toulis KA, Anastasilakis AD Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporosis Int 2009, published online Dec 15. 10.1007/s00198-009-1145-1.
8. Kyrgidis A Denosumab, osteoporosis, and prevention of fractures. N Engl J Med 2009, 361:2189.
9. Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008, 9:1166-1172.